22 enero, 2018 AdminGadea

Antonio Garcia-Garcia


1970 – MD and PhD, Complutense University of Madrid, Spain.

1971-1974. Postdoctoral training, State University of New York, Downstate Medical Center, New York, USA.


Director: Instituto Teófilo Hernando de I+D del Medicamento (ITH), Facultad de Medicina, Universidad Autónoma de Madrid. Head, Servicio de Farmacología Clínica Hospital Universitario de la Princesa, Facultad de Medicina, Universidad Autónoma de Madrid, Spain.


Research interests

Exocytosis-neurotransmission-calcium signalling. I am working for near 40 years on basic ionic and receptor mechanisms involved in the regulation of exocytotic neurotransmitter release. I mostly use the adrenal medullary chromaffin cell as a model to perform electrophysiological, pharmacological and neurosecretory studies, combining calcium imaging techniques with patch-clamp and amperometric techniques. I am particularly interested in developing my hypothesis that the functional triad formed by voltage-dependent calcium channels, the endoplasmic reticulum, and mitochondria shape the cytosolic calcium signals required to regulate pre-exocytotic and exocytotic steps. I am trying to project this hypothesis into pathogenic mechanisms of four disorders i.e. Alzheimer´s disease, amyotrophic lateral sclerosis, fetal and perinatal hypoxia and hypertension.

Design, synthesis and Pharmacology of neuroprotective compounds with potential therapeutic application in neurodegeneratives diseases and stroke. In 1994 I published my first paper, trying to link sodium and calcium channels to basic mechanisms of neuronal death, using the chromaffin cell as a model. In subsequent years, I developed this area, focusing on neurotoxicity mechanisms looking for targets to develop new chemical entities with potential neuroprotective actions and therapeutic applications to neurodegenerative deseases (particularly Alzheimer´s disease) and to cerebrovascular diseases (stroke).

Scientific publications (SCI): 370; Hirsch index: 50..